Elucidating ICI resistance in melanoma with ctDNA and tumor profiling [Video]

Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on findings from a study assessing mechanisms of immune checkpoint inhibitor (ICI) resistance in patients with metastatic melanoma. Blood and tissue samples were collected from 23 patients and a combination of ultra sensitive circulating tumor DNA (ctDNA) and tumor immune profiling were associated with certain markers of resistance and clinical outcomes. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.